The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2 study of BLU-945 in patients with common activating EGFR-mutant non–small cell lung cancer (NSCLC): SYMPHONY trial in progress.
 
Elaine Shum
Consulting or Advisory Role - AstraZeneca; Genentech; Janssen
Research Funding - Delfi Diagnostics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Nektar
 
Yasir Y Elamin
Consulting or Advisory Role - AstraZeneca; Lilly; Sanofi; Takeda; Turning Point Therapeutics
Research Funding - AstraZeneca; Blueprint Medicines; Elevation Oncology; Forward; Lilly; Precision Therapeutics; Spectrum Pharmaceuticals; Takeda; Turning Point Therapeutics; Xcovery
Travel, Accommodations, Expenses - Lilly
 
Zofia Piotrowska
Consulting or Advisory Role - Blueprint Medicines; C4 Therapeutics; Cullinan Oncology; Janssen; Jazz Pharmaceuticals; Takeda
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Cullinan Oncology (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline/Tesaro (Inst); Janssen (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
 
David R Spigel
Leadership - American Society of Clinical Oncology
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Foundation Medicine (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Moderna Therapeutics (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Precision Oncology (Inst); Takeda (Inst); TRM Oncology (Inst)
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); Foundation Medicine (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst); University of Texas Southwestern (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech; Genzyme; Intuitive Surgical; Lilly; Merck; Pfizer; Purdue Pharma; Spectrum Pharmaceuticals
 
Karen L. Reckamp
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Lilly; EMD Serono; Genentech; GlaxoSmithKline; Janssen Oncology; Lilly; Merck KGaA; Mirati Therapeutics; Seagen; Takeda; Tesaro
Research Funding - Blueprint Medicines; Calithera Biosciences (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst)
 
Julia K Rotow
Honoraria - AstraZeneca; Chia Tai Tianqing; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck; Pfizer; Regeneron; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Gritstone Bio; Lilly; Regeneron; Takeda
 
Daniel Shao-Weng Tan
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; C4 Therapeutics; Loxo; Merck; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche
 
Sun Min Lim
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; Takeda; Yuhan
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bridge Medicines (Inst); GlaxoSmithKline (Inst); Hengrui Pharmaceutical (Inst); Oscotec (Inst); Roche (Inst)
 
Tae Min Kim
Consulting or Advisory Role - AstraZeneca/MedImmune; Hanmi; Janssen Oncology; Novartis; Takeda; Yuhan
Speakers' Bureau - Roche/Genentech; Takeda
Research Funding - AstraZeneca
(OPTIONAL) Uncompensated Relationships - AstraZeneca/MedImmune; Bayer; Boryung; Novartis; Roche/Genentech; Sanofi
 
Chia-Chi Lin
Honoraria - Daiichi Sankyo; Lilly; Novartis; Novartis; Roche
Consulting or Advisory Role - Abbvie; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo; Novartis; PharmaEngine
Travel, Accommodations, Expenses - BeiGene; Daiichi Sankyo; Daiichi Sankyo; Lilly; Novartis
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - Amgen; AstraZeneca; Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Lilly; Merck Serono; MSD; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Chugai Pharma (Inst); Haihe Biopharma (Inst); Lilly (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Takeda (Inst); Turning Point Therapeutics (Inst)
 
Jagan Parepally
Employment - Blueprint Medicines
Stock and Other Ownership Interests - Blueprint Medicines
 
Faris Albayya
Employment - Blueprint Medicines
Stock and Other Ownership Interests - Blueprint Medicines
 
Melinda Louie-Gao
Employment - Blueprint Medicines
Stock and Other Ownership Interests - Blueprint Medicines
 
Tessa Weinig
Employment - Blueprint Medicines
Stock and Other Ownership Interests - Blueprint Medicines
 
Alena Zalutskaya
Employment - Blueprint Medicines
Stock and Other Ownership Interests - Blueprint Medicines
 
Koichi Goto
Honoraria - Amgen; Amoy Diagnostics; AstraZeneca Japan; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health; Janssen; Lilly Japan; Merck; Novartis; Ono Pharmaceutical; Otsuka; Takeda
Consulting or Advisory Role - Amgen; Bayer; Janssen; Lilly Japan; Medpace; Takeda
Research Funding - Amgen; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Ignyta; Janssen; Kissei Pharmaceutical; Kyowa Kirin Co., Ltd.; Lilly Japan; Loxo; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck; Merus; MSD K.K.; NEC Corporation; Ono Pharmaceutical; Pfizer; Shanghai HaiHe Pharmaceutical; Spectrum Pharmaceuticals; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; Turning Point Therapeutics